David R Owen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2968876/publications.pdf

Version: 2024-02-01

55 papers

4,347 citations

32 h-index 54 g-index

60 all docs

60 does citations

60 times ranked

6047 citing authors

#	Article	IF	CITATIONS
1	An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1-5.	4.3	642
2	Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [¹¹ C]PBR28 PET Brain Imaging Study. American Journal of Psychiatry, 2016, 173, 44-52.	7.2	382
3	Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. Journal of Nuclear Medicine, 2011, 52, 24-32.	5.0	330
4	Roles of microglia in brain development, tissue maintenance and repair. Brain, 2015, 138, 1138-1159.	7. 6	316
5	Two Binding Sites for [³ H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1608-1618.	4.3	187
6	Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2679-2690.	4.3	153
7	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain, 2018, 141, 459-471.	7.6	143
8	Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank. Journal of Medical Genetics, 2019, 56, 131-138.	3.2	121
9	Determination of [¹¹ C]PBR28 Binding Potential <i>in vivo:</i> A First Human TSPO Blocking Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 989-994.	4.3	117
10	PET imaging of neuroinflammation in neurological disorders. Lancet Neurology, The, 2020, 19, 940-950.	10.2	117
11	Quantification of the Specific Translocator Protein Signal of ¹⁸ F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. Journal of Nuclear Medicine, 2013, 54, 1915-1923.	5.0	105
12	Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biological Psychiatry, 2016, 80, 62-72.	1.3	103
13	Imaging of Atherosclerosis. Annual Review of Medicine, 2011, 62, 25-40.	12.2	101
14	Cellular sources of TSPO expression in healthy and diseased brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 146-163.	6.4	85
15	Inflammation within Carotid Atherosclerotic Plaque: Assessment with Late-Phase Contrast-enhanced US. Radiology, 2010, 255, 638-644.	7.3	82
16	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with ¹⁸ F-PBR111 PET. Journal of Nuclear Medicine, 2014, 55, 1112-1118.	5.0	82
17	<i>TSPO</i> mutations in rats and a human polymorphism impair the rate of steroid synthesis. Biochemical Journal, 2017, 474, 3985-3999.	3.7	80
18	Comparison of four 11C-labeled PET ligands to quantify translocator protein 18ÂkDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176â€"based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Research, 2017, 7, 84.	2.5	80

#	Article	IF	CITATIONS
19	Diverse human astrocyte and microglial transcriptional responses to Alzheimer's pathology. Acta Neuropathologica, 2022, 143, 75-91.	7.7	80
20	Direct and Indirect Effects of Immune and Central Nervous System–Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation. Journal of Immunology, 2015, 194, 761-772.	0.8	75
21	A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain, 2019, 142, 3440-3455.	7.6	7 5
22	Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. Neurolmage, 2012, 60, 902-910.	4.2	73
23	Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. BMC Genomics, 2018, 19, 867.	2.8	61
24	The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory â€~M1' human macrophages. PLoS ONE, 2017, 12, e0185767.	2.5	59
25	¹¹ C-PBR28 and ¹⁸ F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. Journal of Nuclear Medicine, 2017, 58, 1477-1482.	5.0	57
26	¹¹ C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than ¹¹ C-(<i>R</i>)-PK11195. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 393-403.	4.3	51
27	Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18kDa Translocator Protein (TSPO). Psychoneuroendocrinology, 2013, 38, 2826-2829.	2.7	47
28	Activated microglia do not increase <scp>18 kDa</scp> translocator protein (<scp>TSPO</scp>) expression in the multiple sclerosis brain. Glia, 2021, 69, 2447-2458.	4.9	47
29	Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. Journal of Nuclear Medicine, 2018, 59, 1125-1132.	5.0	46
30	Phenibut (4â€aminoâ€3â€phenylâ€butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug and Alcohol Review, 2016, 35, 591-596.	2.1	44
31	Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse, 2011, 65, 257-259.	1.2	42
32	A Graphical Method to Compare the <i>in vivo</i> Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [¹¹ C]PBR28 and [¹⁸ F]PBR111 for TSPO Imaging. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1162-1168.	4.3	38
33	Teaching integrated care: CAM familiarisation courses. Medical Journal of Australia, 2004, 181, 276-278.	1.7	34
34	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. Molecular Imaging and Biology, 2019, 21, 935-944.	2.6	32
35	The impact of the rs6971 polymorphism in TSPO for quantification and study design. Clinical and Translational Imaging, 2015, 3, 417-422.	2.1	28
36	Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 42-47.	2.0	28

#	Article	IF	CITATIONS
37	Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. Acta Neuropathologica, 2021, 142, 449-474.	7.7	27
38	Identification and Assessment of Plasma Lysozyme as a Putative Biomarker of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1027-1033.	2.4	23
39	Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology, 2017, 56, 1837-1846.	1.9	22
40	Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1–Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using ⟨sup⟩11⟨/sup⟩C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. Journal of Nuclear Medicine, 2016, 57, 1905-1912.	5.0	18
41	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. Journal of Psychopharmacology, 2013, 27, 119-122.	4.0	16
42	Assessment of Global Liver Blood Flow With Quantitative Dynamic Contrast-Enhanced Ultrasound. Journal of Ultrasound in Medicine, 2011, 30, 379-385.	1.7	13
43	Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 125-136.	6.4	11
44	A case report of nifedipine-induced hepatitis with jaundice. BMC Research Notes, 2018, 11, 228.	1.4	10
45	Using prescribing very short answer questions to identify sources of medication errors: a prospective study in two UK medical schools. BMJ Open, 2019, 9, e028863.	1.9	10
46	Intravenous Furosemide for Acute Decompensated Congestive Heart Failure: What Is the Evidence?. Clinical Pharmacology and Therapeutics, 2015, 98, 119-121.	4.7	7
47	<p>Using team-based revision to prepare medical students for the prescribing safety assessment</p> . Advances in Medical Education and Practice, 2019, Volume 10, 501-506.	1.5	7
48	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2242-2243.	6.4	4
49	Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3530-3539.	6.4	4
50	The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation study. Anticancer Research, 2014, 34, 3597-606.	1.1	4
51	Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by TSPO. British Journal of Clinical Pharmacology, 2022, , .	2.4	4
52	In Response to Letter from Fregonara et al. 2019. Molecular Imaging and Biology, 2020, 22, 13-14.	2.6	2
53	Imaging immune responses in neuroinflammatory diseases. Clinical and Experimental Immunology, 2021, 206, 248-250.	2.6	2
54	Complementary and alternative medicine (CAM) in the undergraduate medical curriculum: the Southampton experience. Medical Education, 2008, 35, 73-77.	2.1	0

#	Article	lF	CITATIONS
55	PBR28, PBR06 and PBR111 bind two distinct TSPO sites in human brain tissue. Neurolmage, 2010, 52, S30-S31.	4.2	0